Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
Cipla
Baxter
Fish and Richardson
Covington
AstraZeneca
Express Scripts
Citi
Daiichi Sankyo

Generated: November 19, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 022083

« Back to Dashboard

NDA 022083 describes EXELON, which is a drug marketed by Novartis and is included in three NDAs. It is available from three suppliers. There are two patents protecting this drug and four Paragraph IV challenges. Additional details are available on the EXELON profile page.

The generic ingredient in EXELON is rivastigmine. There are thirty-two drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the rivastigmine profile page.
Summary for 022083
Tradename:EXELON
Applicant:Novartis
Ingredient:rivastigmine
Patents:2
Formulation / Manufacturing:see details
Pharmacology for NDA: 022083
Mechanism of ActionCholinesterase Inhibitors
Medical Subject Heading (MeSH) Categories for 022083
Suppliers and Packaging for NDA: 022083
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
EXELON rivastigmine FILM, EXTENDED RELEASE;TRANSDERMAL 022083 NDA Novartis Pharmaceuticals Corporation 0078-0501 0078-0501-15 30 PATCH in 1 CARTON (0078-0501-15) > 24 h in 1 PATCH (0078-0501-61)
EXELON rivastigmine FILM, EXTENDED RELEASE;TRANSDERMAL 022083 NDA Novartis Pharmaceuticals Corporation 0078-0502 0078-0502-15 30 PATCH in 1 CARTON (0078-0502-15) > 24 h in 1 PATCH (0078-0502-61)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:FILM, EXTENDED RELEASE;TRANSDERMALStrength4.6MG/24HR
Approval Date:Jul 6, 2007TE:ABRLD:Yes
Patent:➤ Try a Free TrialPatent Expiration:Jan 8, 2019Product Flag?YSubstance Flag?Delist Request?
Patent:➤ Try a Free TrialPatent Expiration:Jan 8, 2019Product Flag?YSubstance Flag?Delist Request?

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:FILM, EXTENDED RELEASE;TRANSDERMALStrength9.5MG/24HR
Approval Date:Jul 6, 2007TE:ABRLD:Yes
Patent:➤ Try a Free TrialPatent Expiration:Jan 8, 2019Product Flag?YSubstance Flag?Delist Request?

Expired US Patents for NDA 022083

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novartis EXELON rivastigmine FILM, EXTENDED RELEASE;TRANSDERMAL 022083-001 Jul 6, 2007 ➤ Try a Free Trial ➤ Try a Free Trial
Novartis EXELON rivastigmine FILM, EXTENDED RELEASE;TRANSDERMAL 022083-002 Jul 6, 2007 ➤ Try a Free Trial ➤ Try a Free Trial
Novartis EXELON rivastigmine FILM, EXTENDED RELEASE;TRANSDERMAL 022083-005 Aug 31, 2012 ➤ Try a Free Trial ➤ Try a Free Trial
Novartis EXELON rivastigmine FILM, EXTENDED RELEASE;TRANSDERMAL 022083-002 Jul 6, 2007 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

UBS
QuintilesIMS
McKinsey
Deloitte
Medtronic
Baxter
Fuji
Cerilliant
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.